Chemed (CHE) RBC Capital Markets Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
RBC Capital Markets Global Healthcare Conference 2026 summary
20 May, 2026Admission mix and growth strategy
Admissions in 1Q 2026 exceeded 19,000, up 7%, with hospital-directed admissions up nearly 14% and non-hospital pre-admissions up 8.5% in Florida.
Hospital admissions are targeted to remain between 42%-45% of total admissions annually, with fluctuations expected due to seasonality.
Strategic focus on balancing hospital and non-hospital admissions to sustain long-term stability and support census growth, especially in the back half of 2026.
New market entries in Florida, such as Manatee, Pasco, Marion, and Pinellas, are ramping up faster than expected, driven by full-scale launches and strong community engagement.
Brand awareness in the Tampa metro area is benefiting surrounding markets, supporting growth and admissions.
CAP mitigation and financial outlook
Achieved a $32.5 million CAP cushion in Florida in 1Q 2026, with no CAP liability accrued.
New market starts contribute short length of stay patients, supporting CAP mitigation and enabling the intake of longer-stay patients.
Guardrails and daily metrics are in place to manage CAP risk, leveraging historical data and improved KPIs.
Margin targets for the back half of 2026 are 18%-18.5%, supported by a shift toward longer length of stay admissions and responsible census growth.
Consolidation of Florida under one provider number allows flexibility to balance census and CAP across markets.
Expansion and operational initiatives
New inpatient units are being developed in Port St. Lucie and Fort Myers, coming online in 2027, to support higher acuity, short-stay patients and further CAP mitigation.
Inpatient units help absorb the sickest patients, providing CAP cushion for other admissions.
Labor capacity is being scaled up, with hiring targets increased to 50-60 FTEs per month in response to accelerated census growth.
No concerns reported in meeting labor demands or managing marginal compression as census grows.
Latest events from Chemed
- Raised hospice growth outlook, selective expansion, and digital strategies support margin gains.CHE
Bank of America Global Healthcare Conference 202612 May 2026 - VITAS outperformed, boosting guidance, while Roto-Rooter faced margin pressure and revenue decline.CHE
Q1 202628 Apr 2026 - Proxy details director elections, auditor ratification, pay-for-performance, and strong governance.CHE
Proxy filing9 Apr 2026 - 2025 revenue up 4.1%, but margins and EPS fell; 2026 outlook is for stronger growth.CHE
Q4 20257 Apr 2026 - Proxy covers director elections, auditor ratification, say-on-pay, and strong governance practices.CHE
Proxy filing6 Apr 2026 - VITAS shows strong growth and margin prospects, while Roto-Rooter faces a pivotal recovery year.CHE
Oppenheimer 36th Annual Healthcare MedTech & Services Conference19 Mar 2026 - Sustained EPS growth, Medicare cap management, and digital innovation drive robust 2024 results.CHE
BofA Securities 2025 Healthcare Conference2 Mar 2026 - Q2 2024 featured robust VITAS growth, Roto-Rooter declines, and raised full-year guidance.CHE
Q2 20242 Feb 2026 - Expecting high single-digit revenue and 10% EPS growth, with robust M&A and expansion plans.CHE
Jefferies 2024 Global Healthcare Conference31 Jan 2026